Prøve GULL - Gratis
The Strategic Rise of India's Deep-Science Economy
BioSpectrum Asia
|BioSpectrum Asia Feb 2026
India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.
-
With initiatives such as the $12 billion Research, Development and Innovation (RDI) Fund, the BioE3 policy, and regulatory support for advanced genetic technologies, the country is positioning itself for rapid innovation-led growth. A growing talent pool, returning global expertise, expanding pharma GCCs, and capital-efficient manufacturing further strengthen India's advantage. Together, these factors create a strong foundation for globally competitive, sustainable science-driven enterprises.
India’s biotech industry is currently undergoing a long awaited shift from being the generics capital of the world to an innovation hub. More than $900 million have been invested into cutting edge IP led startups in therapeutics, diagnostics and industrial biotech over the last seven years, according to Ankur Capital’s Deep Science Tech Report 2025. The journey of deep science biotechnology driven startups in India began in the early 2010’s with companies such as String Bio, Bugworks and Zumutor Biologics pushing the boundaries to develop novel drugs and agri inputs using synthetic biology and precision fermentation. While their journey has been long and hard and yet to see large outcomes, they laid the foundations for cutting edge innovations in biotechnology emerging from India for the world.
Denne historien er fra BioSpectrum Asia Feb 2026-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia
BioSpectrum Asia
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO
Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Ambitious research to develop multivalent vaccines against multiple deadly filoviruses
Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Korea opens door to B cell-based personalised cancer vaccines
Researchers from the Department of Bio and Brain Engineering at Korea Advanced Institute of Science and Technology (KAIST), in collaboration with Neogen Logic Co., have developed a new artificial intelligence (AI) model to predict neoantigens, a core element of personalised cancer vaccine development, and clarified the importance of B cells in cancer immunotherapy.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Chad May steps in as Chief Scientific Officer at Orum Therapeutics
Orum Therapeutics, a biotechnology company based in the US and South Korea, has announced the appointment of Dr Chad May as Chief Scientific Officer (CSO).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
PAHO reviews measles elimination status in United States and Mexico
The Pan American Health Organization (PAHO) Regional Monitoring and Re-Verification Commission for Measles, Rubella, and Congenital Rubella Syndrome (RVC) has invited the United States and Mexico to meet virtually on April 13, 2026, to review their measles elimination status.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
US FDA approves first treatment for children with Menkes Disease
The US Food and Drug Administration (FDA) has approved the Zycubo (copper histidinate) injection, to Sentynl Therapeutics, as the first treatment for Menkes disease in paediatric patients.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
SINGAPORE SHOWS WHAT TARIFFS CAN'T
While U.S. President Donald Trump was publicly defending his threat of higher import tariffs on medicines, Singapore was quietly experiencing an unexpected upside: a surge in pharmaceutical production.
2 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Hong Kong designs mucus-inspired hydrogel to boost gastrointestinal wound healing
The Hong Kong Polytechnic University (PolyU) has developed an acid-resistant “ultra-stable mucus-inspired hydrogel” (UMIH), marking a breakthrough in the field of gastrointestinal medicine.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Africa lifts Mpox as Public Health Emergency of Continental Security
Africa has officially lifted Mpox as a Public Health Emergency of Continental Security following recommendations from the Africa CDC Emergency Consultative Group.
1 min
BioSpectrum Asia Feb 2026
Listen
Translate
Change font size
